BNBXApplied Dna Sciences Inc

Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market session. The market value of their outstanding shares is at $74.6 million. BNB Plus (NASDAQ:BNBX) stock rose 9.78% toread more...

BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced it has secured initial commitments for $4.1M of convertible preferred stock financing, with additional commitments anticipated to bring total proceeds to $5.0M (the "Financing"). Proceeds from the Financing will be used to...

BNB Plus Corp. (Nasdaq: BNBX) ('BNB Plus' or the 'Company'), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has successfully completed production of its largest...

BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update...

Large banks and tech organizations have early access to Mythos, while crypto companies still rely on older AI models and internal security technologies.

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has been granted a European patent by the European Patent...

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company') today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ('LineaRx'), has received two new orders for LineaDNA from...

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), today announced the appointment of James Haft as an Independent Director and member of the Boards Nominating Committee, effective as of...

BNB Plus Corp. (Nasdaq: BNBX) ('BNBX' or the 'Company'), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital...